Triptocallic acid D is primarily used in pharmaceutical research due to its potential anti-inflammatory and immunomodulatory properties. It has shown activity in suppressing pro-inflammatory cytokines, making it a candidate for development in treatments for autoimmune diseases such as rheumatoid arthritis and lupus. Studies also indicate its role in inhibiting certain signaling pathways involved in chronic inflammation and tissue damage. Additionally, it is being explored for its neuroprotective effects, with potential applications in neurodegenerative conditions like Alzheimer’s disease. Due to its natural origin and bioactivity, it serves as a lead compound in the design of new synthetic analogs with improved efficacy and stability.